Furthermore, various cancer treatments can induce resistance in parallel with the conversion of the epithelial tumor to a neuroendocrine variant: anti-androgens induce such an alteration in prostate cancer [17], while EGFR inhibitors induce similar conversion in lung adenocarcinomas [18]. This evidence concerns the gene EGFR and lung adenocarcinoma.